{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:03:43Z","timestamp":1761102223336},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Grants-in-Aid from Japan Society for the Promotion of Science","award":["26461183, 26462000"],"award-info":[{"award-number":["26461183, 26462000"]}]},{"name":"Grant-in-Aid for Research on seeds for Publicly Essential Drugs and Medical Devices from the Ministry of Health, Labor and Welfare of Japan","award":["H23 seisaku ippan 009"],"award-info":[{"award-number":["H23 seisaku ippan 009"]}]},{"name":"Grant-in-aid from the Nichias Corporation","award":["none"],"award-info":[{"award-number":["none"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2483-y","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T10:22:10Z","timestamp":1468318930000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma"],"prefix":"10.1186","volume":"16","author":[{"given":"Yuanyuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boya","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoko","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"issue":"8","key":"2483_CR1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tips.2011.03.011","volume":"32","author":"RE Favoni","year":"2011","unstructured":"Favoni RE, Florio T. Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma. Trends Pharmacol Sci. 2011;32(8):463\u201379.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"2483_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30227","volume":"29","author":"M Carbone","year":"2002","unstructured":"Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002;29(1):2\u201317.","journal-title":"Semin Oncol"},{"issue":"8","key":"2483_CR3","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/cncr.22552","volume":"109","author":"AY Lee","year":"2007","unstructured":"Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer. 2007;109(8):1454\u201361.","journal-title":"Cancer"},{"issue":"3","key":"2483_CR4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/cgt.2013.1","volume":"20","author":"M Tagawa","year":"2013","unstructured":"Tagawa M, Tada Y, Shimada H, Hiroshima K. Gene therapy for malignant mesothelioma: Current prospects and challenges. Cancer Gene Ther. 2013;20(3):150\u20136.","journal-title":"Cancer Gene Ther"},{"issue":"20","key":"2483_CR5","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2174\/092986707781389600","volume":"14","author":"T Yuasa","year":"2007","unstructured":"Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid: a multiplicity of anti-cancer action. Curr Med Chem. 2007;14(20):2126\u201335.","journal-title":"Curr Med Chem"},{"issue":"6","key":"2483_CR6","first-page":"2602","volume":"61","author":"MV Lee","year":"2001","unstructured":"Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61(6):2602\u20138.","journal-title":"Cancer Res"},{"issue":"8","key":"2483_CR7","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"SG Senaratne","year":"2000","unstructured":"Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82(8):1459\u201368.","journal-title":"Br J Cancer"},{"issue":"Suppl 4","key":"2483_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","volume":"9","author":"JR Green","year":"2004","unstructured":"Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9 Suppl 4:3\u201313.","journal-title":"Oncologist"},{"issue":"6","key":"2483_CR9","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s13277-015-3140-9","volume":"36","author":"RM Jones","year":"2015","unstructured":"Jones RM, Morgan C, Bertelli G. Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer. Tumor Biol. 2015;36(6):4861\u20139.","journal-title":"Tumor Biol"},{"issue":"5","key":"2483_CR10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JTO.0b013e31824c7d43","volume":"7","author":"S Okamoto","year":"2012","unstructured":"Okamoto S, Kawamura K, Li Q, Yamanaka M, Yang S, Fukamachi T, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Kobayashi H, Tagawa M. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners. J Thorac Oncol. 2012;7(5):873\u201382.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2483_CR11","doi-asserted-by":"crossref","first-page":"e60297","DOI":"10.1371\/journal.pone.0060297","volume":"8","author":"S Okamoto","year":"2013","unstructured":"Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Fukamachi T, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Hiroshima K, Kobayashi H, Tagawa M. Zoledronic acid produces combinatory anti-tumor effects with cisplatin on mesothelioma by increasing p53 expression levels. PLoS One. 2013;8(3):e60297.","journal-title":"PLoS One"},{"issue":"16","key":"2483_CR12","first-page":"5959","volume":"61","author":"CT Yang","year":"2001","unstructured":"Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 2001;61(16):5959\u201363.","journal-title":"Cancer Res"},{"key":"2483_CR13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s12885-015-1482-8","volume":"15","author":"S Yang","year":"2015","unstructured":"Yang S, Kawamura K, Okamoto S, Yamauchi S, Shingyoji M, Sekine I, Kobayashi H, Tada Y, Tatsumi K, Hiroshima K, Shimad H, Tagawa, M. Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression. BMC Cancer. 2015;15:464.","journal-title":"BMC Cancer"},{"issue":"5286","key":"2483_CR14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274(5286):373\u20136.","journal-title":"Science"},{"issue":"7310","key":"2483_CR15","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nature09307","volume":"466","author":"C Soria","year":"2010","unstructured":"Soria C, Estermann FE, Espantman KC, O\u2019Shea CC. Heterochromatin silencing of p53 target genes by a small viral protein. Nature. 2010;466(7310):1076\u201381.","journal-title":"Nature"},{"issue":"12","key":"2483_CR16","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1128\/JVI.72.12.9470-9478.1998","volume":"72","author":"T Rothmann","year":"1998","unstructured":"Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 1998;72(12):9470\u20138.","journal-title":"J Virol"},{"issue":"12","key":"2483_CR17","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1097\/JTO.0b013e3182725fa4","volume":"7","author":"M Yamanaka","year":"2012","unstructured":"Yamanaka M, Tada Y, Kawamura K, Li Q, Okamoto S, Chai K, Yokoi S, Liang M, Fukamachi T, Kobayashi H, Yamaguchi N, Kitamura A, Shimada H, Hiroshima K, Takiguchi Y, Tatsumi K, Tagawa M. E1B-55\u00a0kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agents. J Thorac Oncol. 2012;7(12):1850\u20137.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2483_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1349-7006.2006.00163.x","volume":"97","author":"E Nakataki","year":"2006","unstructured":"Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K, Yokoyama A, Sone S. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci. 2006;97(3):183\u201391.","journal-title":"Cancer Sci"},{"issue":"4","key":"2483_CR19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/cc.27546","volume":"13","author":"D Marzo Di","year":"2014","unstructured":"Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 2014;13(4):652\u201365.","journal-title":"Cell Cycle"},{"issue":"1","key":"2483_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1124\/mol.106.028837","volume":"71","author":"B Ory","year":"2007","unstructured":"Ory B, Blanchard F, Battaglia S, Gouin F, R\u00e9dini F, Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007;71(1):333\u201343.","journal-title":"Mol Pharmacol"},{"issue":"7","key":"2483_CR21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34(7):1413\u20139.","journal-title":"Carcinogenesis"},{"issue":"2","key":"2483_CR22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrc3876","volume":"15","author":"T Moroishi","year":"2015","unstructured":"Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15(2):73\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2483_CR23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JTO.0b013e31811f3aab","volume":"2","author":"MR Patel","year":"2007","unstructured":"Patel MR, Jacobson BA, De A, Frizelle SP, Janne P, Thumma SC, Whitson BA, Farassati F, Kratzke RA. Ras pathway activation in malignant mesothelioma. J Thorac Oncol. 2007;2(9):789\u201395.","journal-title":"J Thorac Oncol"},{"key":"2483_CR24","doi-asserted-by":"crossref","first-page":"e1517","DOI":"10.1038\/cddis.2014.475","volume":"5","author":"S Okamoto","year":"2014","unstructured":"Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada H, Hiroshima K, Tagawa M. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions. Cell Death Dis. 2014;5:e1517.","journal-title":"Cell Death Dis"},{"issue":"44","key":"2483_CR25","doi-asserted-by":"crossref","first-page":"43603","DOI":"10.1074\/jbc.M308114200","volume":"278","author":"M Bezzi","year":"2003","unstructured":"Bezzi M, Hasmim M, Bieler G, Dormond O, R\u00fcegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B\/Akt. J Biol Chem. 2003;278(44):43603\u201314.","journal-title":"J Biol Chem"},{"issue":"11","key":"2483_CR26","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1128\/JVI.72.11.8806-8812.1998","volume":"72","author":"E Li","year":"1998","unstructured":"Li E, Stupack D, Bokoch GM, Nemerow GR. Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. J Virol. 1998;72(11):8806\u201312.","journal-title":"J Virol"},{"issue":"1","key":"2483_CR27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/JVI.71.1.548-561.1997","volume":"71","author":"FD Goodrum","year":"1997","unstructured":"Goodrum FD, Ornelles DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol. 1997;71(1):548\u201361.","journal-title":"J Virol"},{"key":"2483_CR28","first-page":"115","volume":"2","author":"G Ma","year":"2008","unstructured":"Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China. Drug Des Dev Ther. 2008;2:115\u201322.","journal-title":"Drug Des Dev Ther"},{"key":"2483_CR29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s40064-016-1893-2","volume":"5","author":"Y Tada","year":"2016","unstructured":"Tada Y, Hiroshima K, Shimada H, Shingyoji M, Suzuki T, Umezawa H, Sekine I, Takiguchi Y, Tatsumi K, Tagawa, M. An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: A phase I clinical study protocol. SpringerPlus. 2016;5:195.","journal-title":"SpringerPlus"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2483-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T20:42:56Z","timestamp":1600893776000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2483-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2483"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2483-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,12]]},"article-number":"455"}}